Compare AVAV & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVAV | NUVL |
|---|---|---|
| Founded | 1971 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 9.8B |
| IPO Year | 2006 | 2021 |
| Metric | AVAV | NUVL |
|---|---|---|
| Price | $173.90 | $123.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 16 |
| Target Price | ★ $316.88 | $134.75 |
| AVG Volume (30 Days) | 1.7M | ★ 4.3M |
| Earning Date | 03-10-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $135.55 | N/A |
| Revenue Next Year | $14.90 | $1,239.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $135.20 | $71.14 |
| 52 Week High | $417.86 | $123.80 |
| Indicator | AVAV | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 66.76 |
| Support Level | $156.00 | $98.56 |
| Resistance Level | $220.08 | N/A |
| Average True Range (ATR) | 10.92 | 0.18 |
| MACD | 3.21 | -0.46 |
| Stochastic Oscillator | 57.10 | 86.41 |
AeroVironment Inc supplies unmanned aircraft systems, tactical missile systems, high-altitude pseudo-satellites, and other related services to government agencies within the United States Department of Defense as well as the United States allied international governments. The systems can help with security, surveillance, or sensing, and provide eyes in the sky without needing an actual person, or driver in the sky. The company is a defense technology provider delivering integrated capabilities across air, land, sea, space, and cyber. It develops and deploy autonomous systems, precision strike systems, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities. Company operates in three segments: UxS, LMS, MW.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.